Acute on Chronic Liver Failure (ACLF) Market Report 2026

The acute on chronic liver failure (aclf) market size has grown strongly in recent years. It will grow from $2.88 billion in 2025 to $3.1 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to rising prevalence of chronic liver diseases, increasing hospitalization rates for liver complications, adoption of pharmacological treatments for ACLF, growing awareness of systemic inflammation in liver failure, limited availability of specialized care centers.

The acute on chronic liver failure (aclf) market size is expected to see strong growth in the next few years. It will grow to $4.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to technological advancements in liver support therapies, expansion of icu and specialty care facilities, increasing investment in pharmacological research, growth in early diagnosis and biomarker identification, integration of digital monitoring and patient management systems. Major trends in the forecast period include increasing adoption of liver dialysis and plasma exchange, rising demand for advanced immunomodulators and antiviral agents, growing focus on nutritional support and patient management, expansion of mechanical ventilation and renal replacement therapy (rrt), improved early diagnosis and monitoring of aclf patients.

The increasing focus on precision and personalized medicine is expected to drive the growth of the acute-on-chronic liver failure market going forward. Precision and personalized medicine involve tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The adoption of precision and personalized medicine is rising due to advancements in genomics, increased availability of biomarker-based diagnostics, improved data analytics technologies, and growing demand for more targeted and effective therapies. Precision and personalized medicine support acute-on-chronic liver failure (ACLF) by customizing treatments according to a patient’s genetic profile, disease severity, and biomarker information, enabling targeted therapies that enhance outcomes and reduce the risk of multi-organ failure. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from the 12 approved in 2022. Therefore, the increasing focus on precision and personalized medicine is fueling the growth of the acute-on-chronic liver failure market.

Major companies operating in the acute-on-chronic liver failure (ACLF) market are focusing on conducting clinical trials to develop novel therapeutics, regenerative medicine approaches, and targeted drug therapies aimed at improving patient survival. Clinical trials are essential for validating new treatment protocols, artificial liver support systems, and immunomodulatory therapies to enhance disease management and reduce mortality. For instance, in September 2024, A-TANGO, a Spain-based EU Horizon-funded project, conducted the clinical "G-TAK trial" in multiple liver centers in the UK, aiming to assist critically ill patients with alcoholic hepatitis and acute-on-chronic liver failure (ACLF). G-TAK is a combinatorial therapy combining a toll-like 4 receptor antagonist (TAK242) to target inflammation with granulocyte colony-stimulating factor (G-CSF, TRL9) to promote hepatocyte proliferation, thereby addressing acute-on-chronic liver failure (ACLF).

In June 2024, the European Foundation for the Study of Chronic Liver Failure (EF CLIF), a Spain-based research foundation, partnered with GENFIT to advance research and therapies for acute-on-chronic liver failure (ACLF). Through this collaboration, EF CLIF and GENFIT aim to expand research into ACLF, exploring novel therapeutic strategies to better understand its pathophysiology, develop predictive biomarkers, and identify treatment targets. GENFIT is a France-based late-stage biopharmaceutical company focused on liver disease, with a pipeline of five ACLF-targeted assets.

Major companies operating in the acute on chronic liver failure (aclf) market are Pfizer Inc., F Hoffmann La Roche AG, Merck and Co Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Novo Nordisk AS, Astellas Pharma Inc., CSL Behring, Grifols SA, Ferring Pharmaceuticals, Lupin Pharmaceutical Limited, Dr Falk Pharma GmbH, Genfit, Conatus Pharmaceuticals Inc., Gyre Therapeutics Inc., Abbott Laboratories.

North America was the largest region in the acute on chronic liver failure (ACLF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute on chronic liver failure (aclf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute on chronic liver failure (aclf) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the ACLF market by increasing the cost of imported pharmacological drugs, liver dialysis equipment, and medical consumables. Segments such as liver dialysis systems, plasma exchange devices, and antiviral medications are most affected, particularly in north america, europe, and asia-pacific regions. This has led to higher treatment costs and supply chain delays. On the positive side, tariffs have encouraged local manufacturing, domestic production of critical medical devices, and innovation in supportive care solutions.

The acute on chronic liver failure (aclf) market research report is one of a series of new reports that provides acute on chronic liver failure (aclf) market statistics, including acute on chronic liver failure (aclf) industry global market size, regional shares, competitors with a acute on chronic liver failure (aclf) market share, detailed acute on chronic liver failure (aclf) market segments, market trends and opportunities, and any further data you may need to thrive in the acute on chronic liver failure (aclf) industry. This acute on chronic liver failure (aclf) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute on chronic liver failure (ACLF) is a severe condition marked by acute hepatic decompensation in patients with pre-existing chronic liver disease. This sudden deterioration triggers systemic inflammation, leading to progressive failure of multiple organs. The condition carries a high risk of mortality and requires prompt diagnosis and intensive medical management.

The main treatment types for acute on chronic liver failure (ACLF) are pharmacological therapy and supportive care. Pharmacological treatment involves the use of medications such as antibiotics, vasopressors, corticosteroids, albumin therapy, and liver-specific drugs to manage infections, reduce inflammation, support organ function, and stabilize the patient prior to potential liver transplantation. Treatments are administered through various modes, including oral and intravenous (IV), and are provided to end users such as hospitals, ambulatory surgical centers, and specialty clinics.

The acute on chronic liver failure (ACLF) market consists of revenues earned by entities by providing services such as diagnostic evaluations, intensive care management, liver function monitoring, hemodialysis, extracorporeal liver support therapies, nutritional support, palliative care and liver transplantation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute on chronic liver failure (ACLF) market also includes sales of diagnostic tools and liver support devices aimed at managing disease progression and improving patient outcomes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.